Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 14/20 | 0.41 |
| ▸ | BRD4 | O60885 | 7/20 | 0.34 |
| ▸ | TAF1 | P21675 | 1/20 | 0.34 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.34 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74771 | 0.87 | PLK1 (0.53) | PLK1BRD4TAF1PLK3PLK2 | |
| SCHEMBL88829 | 0.78 | PLK1 (0.47) | PLK1BRD4PLK3PLK2 | |
| SCHEMBL88828 | 0.78 | PLK1 (0.47) | PLK1BRD4PLK3PLK2 | |
| SCHEMBL84917 | 0.76 | PLK1 (0.55) | PLK1PLK3PLK2 | |
| SCHEMBL92591 | 0.74 | PLK1 (0.53) | PLK1BRD4PLK3PLK2 | |
| SCHEMBL6127769 | 0.73 | PLK1 (0.59) | PLK1BRD4TAF1PLK3PLK2 | |
| SCHEMBL16405219 | 0.72 | BRD4 (0.50) | PLK1BRD4TAF1BRDTPLK3 | |
| SCHEMBL31098067 | 0.71 | BRD4 (0.49) | PLK1BRD4TAF1BRDTPLK3 | |
| SCHEMBL16178620 | 0.69 | BRD4 (0.38) | PLK1BRD4TAF1BRDTPLK3 | |
| SCHEMBL3261703 | 0.69 | PLK1 (0.51) | PLK1BRD4PLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-25 | — | — | US | disclosed |
| WO-2010025073-A1 | DIHYDROIMIDAZO [ 1, 5-F] PTERIDINES AS POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | PLK2, PLK4, PLK1 | PLK1 3/4885BRD4 1842/4885TAF1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.